EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 1b

Ensembl ID : ENSCLMG00005008029
Gene Symbol: ATP1B1B
1 Cross references
215 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSCLMG00005017612
Gene Symbol: ATP1B2
1 Cross references
193 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSCLMG00005022508
Gene Symbol: ATP1B2B
1 Cross references
197 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3a

Ensembl ID : ENSCLMG00005008800
Gene Symbol: ATP1B3A
1 Cross references
229 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSCLMG00005021055
Gene Symbol: ATR
1 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSCLMG00005010942
Gene Symbol: AXL
1 Cross references
188 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCLMG00005011977
Gene Symbol: BRAF
1 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCLMG00005016560
Gene Symbol: BCL2L1
1 Cross references
229 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSCLMG00005013107
Gene Symbol: BCL2L1
1 Cross references
216 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSCLMG00005018784
Gene Symbol: BCL2L10
1 Cross references
129 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSCLMG00005020071
Gene Symbol: BCR
1 Cross references
209 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSCLMG00005008452
Gene Symbol: BTK
1 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).